BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23922218)

  • 1. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
    Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
    Cytometry B Clin Cytom; 2014 Jul; 86(4):220-8. PubMed ID: 23922218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
    Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
    Cytometry B Clin Cytom; 2013 Jul; ():. PubMed ID: 23893930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.
    Muthu Raja KR; Kubiczkova L; Rihova L; Piskacek M; Vsianska P; Hezova R; Pour L; Hajek R
    PLoS One; 2012; 7(11):e49446. PubMed ID: 23152910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
    Scott GB; Carter C; Parrish C; Wood PM; Cook G
    Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
    Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
    Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
    Gay F; Hayman SR; Lacy MQ; Buadi F; Gertz MA; Kumar S; Dispenzieri A; Mikhael JR; Bergsagel PL; Dingli D; Reeder CB; Lust JA; Russell SJ; Roy V; Zeldenrust SR; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Rajkumar SV
    Blood; 2010 Feb; 115(7):1343-50. PubMed ID: 20008302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low frequency of CD3
    Lee SE; Lim JY; Ryu DB; Kim TW; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK
    Ann Hematol; 2018 Nov; 97(11):2163-2171. PubMed ID: 29938309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of thalidomide on CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma].
    Yang Y; Zhang WG; He AL; Yang HY; Wang JL; Tian W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):538-42. PubMed ID: 18549624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
    Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
    Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.
    Mitani Y; Usami E; Kimura M; Nakao T; Okada K; Matsuoka T; Kokuryou T; Yoshimura T; Yamakawa M
    Pharmazie; 2016 Jun; 71(6):349-51. PubMed ID: 27455556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
    Dimopoulos MA; Terpos E; Goldschmidt H; Alegre A; Mark T; Niesvizky R
    Cancer Treat Rev; 2012 Dec; 38(8):1012-9. PubMed ID: 22609463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
    Minnema MC; van der Veer MS; Aarts T; Emmelot M; Mutis T; Lokhorst HM
    Leukemia; 2009 Mar; 23(3):605-7. PubMed ID: 18784738
    [No Abstract]   [Full Text] [Related]  

  • 18. Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.
    Shannon E; Sandoval F; Greig N; Stagg P
    Int Immunopharmacol; 2012 Feb; 12(2):441-6. PubMed ID: 22245427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
    Zonder JA; Crowley J; Hussein MA; Bolejack V; Moore DF; Whittenberger BF; Abidi MH; Durie BG; Barlogie B
    Blood; 2010 Dec; 116(26):5838-41. PubMed ID: 20876454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.
    Ishak KJ; Caro JJ; Drayson MT; Dimopoulos M; Weber D; Augustson B; Child JA; Knight R; Iqbal G; Dunn J; Shearer A; Morgan G
    Value Health; 2011; 14(5):672-8. PubMed ID: 21839405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.